A novel biological assay to detect the active form of TGF-β in urine to monitor renal allograft rejection

Abstract

We describe a highly sensitive and specific assay for active TGF-beta. We also show that, in cases of renal allograft, TGF-beta expression is highly and significantly correlated with acute or chronic rejections.

Tenascin-X promotes epithelial-to-mesenchymal transition by activating latent TGF-β

“…FBG-induced activation of latent TGF-β must either involve an intrinsic activity of this domain or require a cell surface adhesion receptor. To discriminate between these hypotheses, we monitored the TGF-β–Smad signaling activity in the TGF-β reporter Burkitt’s lymphoma (BL41-(CAGA) 9 -Luc) cell line (Rogier et al, 2005), which did not adhere to the coated FBG domain (Fig. 9 A).…”

Urinary active transforming growth factor β in feline chronic kidney disease

“…There is limited information on urinary aTGF-β1 in the veterinary and medical literature. A previous study in humans detected urinary aTGF-β1 in 25% of patients with active nephropathy subsequent to allograft dysfunction, but aTGF-β1 was undetectable in the urine of patients with normal renal function ( Rogier et al., 2005 ). In contrast, the majority of healthy geriatric cats in this study demonstrated low, but detectable, concentrations of aTGF-β1.…”

Identification of β2‐microglobulin as a urinary biomarker for chronic allograft nephropathy using proteomic methods

“…In fact, Schaub et al identified β2 microglobulin as a potential biomarker for acute renal transplant rejection 33. Several potential biomarkers for CAN have been reported in the past including retinol‐binding protein 34, transforming growth factor β 35, and α‐1 microglobulin 36 but there have not been any urinary biomarker patterns or biomarker proteins identified with SELDI‐TOF‐MS analysis for CAN.…”